Related Experiment Video

Updated: Mar 18, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Current status of glucose test prescription for hypertensive outpatients

Yiqiang Zhan1, Dayi Hu2, Jinming Yu1

  • 1a School of Public Health , Institute of Clinical Epidemiology, Fudan University , Shanghai , P. R. China.

Clinical and Experimental Hypertension (New York, N.Y. : 1993)
|July 9, 2016
PubMed

Insights

Glucose testing is underutilized in hypertensive patients in China, with only 4.92% receiving tests. Increased awareness among cardiologists is recommended for high-risk individuals to improve diabetes detection.

Area of Science:

  • Cardiology
  • Endocrinology
  • Public Health

Background:

  • Essential hypertension is a significant cardiovascular risk factor.
  • Early detection of glucose metabolism abnormalities is crucial for managing hypertensive patients.
  • Current glucose test prescription rates for hypertensive outpatients are not well-documented.

Purpose of the Study:

  • To investigate the rate of glucose test prescription among hypertensive outpatients in China.
  • To identify factors associated with glucose test prescription in this population.

Main Methods:

  • A consecutive sample of 5240 hypertensive outpatients without known diabetes was recruited from over 90 hospitals.
  • Blood glucose test prescription records were collected by dedicated investigators.

Main Results:

  • Only 4.92% (258/5240) of hypertensive outpatients were prescribed glucose tests.
  • Among those tested, 12.17% were diagnosed with diabetes mellitus and 42.61% with impaired glucose tolerance.
  • Hypertension stage, cardiovascular disease history, family history of diabetes, dyslipidemia, and hospital level were linked to higher prescription odds.

Conclusions:

  • Glucose test prescription for hypertensive outpatients in China is notably low.
  • Cardiologists should enhance awareness regarding glucose testing for hypertensive patients with cardiovascular risk factors.
  • Improved screening can aid in the early diagnosis of diabetes and related conditions.
Abstract

Keywords:
Cardiovascular diseasediabetesglucosehypertension

More Related Videos

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli08:01

A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli

Published on: August 12, 2016

9.6K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.5K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
705
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
602
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.3K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
879